Clinical Trial Update: A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Ivonescimab in combination with chemotherapy as neoadjuvant therapy for borderline resectable pancreatic cancer and is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: RECRUITING